Yea Christopher sold 33,800 shares of KalVista Pharmaceuticals, Inc. at $26.78 for −$905k on May 27, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CHIEF DEVELOPMENT OFFICER
CHIEF DEVELOPMENT OFFICER
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$905,224.84Shares × reported price
Shares traded
33,800Common Stock
Price per share
$26.78Reported price. Read footnotes for ranges.
% of reported position traded
12.82%This security and ownership context
Holdings after
229,918Direct
Trade date
May 27, 2026Sell
Filed
May 29, 2026, 4:05 PM ET2-day reporting delay
Accession
0001691102-26-000007Code S · Transaction 93924
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 263,718 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 27, 2026Option exercise33,800$0.00$0Trade 93925
May 27, 2026Option exercise33,800$7.07$238,966Trade 93923
3 transaction rows in this filing. Joint filers share the same rows.

KALV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KALV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −29%1w ago −0.2%1d ago −0.2%
Returns since7d +0.3%30d +0.5%90d180d1y

Footnotes in full

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.78 to $26.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: This option is 100% vested and exercised.